No profile data available.
Protagonist Therapeutics, Inc. (PTGX) is a healthcare company in the blood disorder treatment drugs industry, based in Newark, United States, with about 141 full-time employees.
It reported revenue of $46.02 million for fiscal year 2025, down 89.4% from fiscal year 2024, and net income of -$130.15 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $213.48 million, up 3749.2% from a year before. Its market capitalization was $9.30 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
Protagonist Therapeutics reported $46.02 million in revenue for fiscal year 2025, down 89.4% from $434.43 million in fiscal year 2024. In Q2 2026 revenue was $213.48 million.
$9.30 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (blood disorder treatment drugs) include Incyte Corporation (INCY), Agios Pharmaceuticals, Inc. (AGIO), uniQure N.v. (QURE), Ultragenyx Pharmaceutical Inc. (RARE).